Mesenchymal Stem-Cell Derived Exosome Therapy as a Potential Future Approach for Treatment of Male Infertility Caused by Chlamydia Infection.

Abstract

Some microbial sexually transmitted infections (STIs) have adverse effects on the reproductive tract, sperm function, and male fertility. Given that STIs are often asymptomatic and cause major complications such as urogenital inflammation, fibrosis, and scarring, optimal treatments should be performed to prevent the noxious effect of STIs on male fertility. Among STIs, Chlamydia trachomatis is the most common asymptomatic preventable bacterial STI. C. trachomatis can affect both sperm and the male reproductive tract. Recently, mesenchymal stem cells (MSCs) derived exosomes have been considered as a new therapeutic medicine due to their immunomodulatory, anti-inflammatory, anti-oxidant, and regenerative effects without consequences through the stem cell transplantation based therapies. Inflammation of the genital tract and sperm dysfunction are the consequences of the microbial infections, especially Chlamydia trachomatis. Exosome therapy as a noninvasive approach has shown promising results on the ability to regenerate the damaged sperm and treating asthenozoospermia. Recent experimental methods may be helpful in the novel treatments of male infertility. Thus, it is demonstrated that exosomes play an important role in preventing the consequences of infection, and thereby preventing inflammation, reducing cell damage, inhibiting fibrogenesis, and reducing scar formation. This review aimed to overview the studies about the potential therapeutic roles of MSCs-derived exosomes on sperm abnormalities and male infertility caused by STIs.

• Authors: Mahin Izadi, Laleh Dehghan Marvast, Mohammad Ebrahim Rezvani, Marzieh Zohrabi, Ali Aliabadi, Seyed Alireza Mousavi, Behrouz Aflatoonian
• Journal: Frontiers in microbiology (Front Microbiol) Vol. 12 Pg. 785622 ( 2021) ISSN: 1664-302X [Print] Switzerland
• PMID: 35095800 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2022 Izadi, Dehghan Marvast, Rezvani, Zohrabi, Aliabadi, Mousavi and Aflatoonian.